TABLE 5.
Clinico-pathological characteristics of p53 assessed patients.
| Variable | No. | % |
| Age | ||
| Median, range (year) | 62, 32–70 | |
| Gender | ||
| Male | 34 | 64.1 |
| Female | 19 | 35.9 |
| Side | ||
| Left | 31 | 58.5 |
| Right | 22 | 41.5 |
| Grading | ||
| G1/G2 | 10 | 18.9 |
| G3 | 43 | 81.1 |
| Lymphnodal involvementa | ||
| No | 24 | 45.3 |
| Yes | 23 | 43.3 |
| Unknown | 6 | 11.4 |
| pTa | ||
| T1/T2 | 14 | 26.4 |
| T3 | 27 | 50.9 |
| T4 | 6 | 11.3 |
| Unknown | 6 | 11.3 |
| No. of metastatic sites | ||
| 1 | 31 | 58.5 |
| ≥2 | 22 | 41.5 |
| RAS (K or N) | ||
| Mutated | 30 | 56.6 |
| Wild-type | 23 | 43.4 |
| BRAF | ||
| Mutated | 5 | 9.4 |
| Wild-type | 48 | 90.6 |
| Previous adjuvant therapy | ||
| Yes | 22 | 41.5 |
| No | 31 | 58.5 |
| No. of treatment lines | ||
| 1 | 5 | 9.4 |
| 2 | 6 | 11.3 |
| >2 | 42 | 79.2 |
| Response to first-line CTb | ||
| DC | 34 | 64.1 |
| No DC | 14 | 26.4 |
| Not assessed | 5 | 9.4 |
CT, chemotherapy; DC, disease control.
aThe sum of cases does not correspond to the total number of patients because some of them (6) did not receive surgical removal of primary tumor.
bThe sum does not correspond to the total number of patients because some of them (5) did not undergo to radiologic reassessment of disease.